Become a Member | Print Page | Contact Us | Sign In
HCAA Webinar: Developments in Chemotherapy
Tell a Friend About This EventTell a Friend
 

8/6/2015
When: 8/6/2015
1:00 PM
Presenter: Joe Hodges


Online registration is closed.
« Go to Upcoming Event List  

DATE:
Thursday, August 6, 2015
10:00 am PT/ 1:00 pm EST

SUBJECT: 
Developments in Chemotherapy

PRESENTER: 
Joe Hodges, President & CEO, INETICO, Inc. 


ABOUT THE PROGRAM:
Today’s oncologists are, on average, only able to identify the correct chemotherapy treatment 25% of the time. This low percentage of accuracy results in devastating effects on the patient’s health as well as incurring revenue effects on the plan in the form of costly and unnecessary multiple rounds of chemo, inpatient admissions and even stoploss lasers.

Recent developments in live cancer tissue testing have now narrowed the margin of error and improved the accurate delivery of chemotherapy to roughly 100%.  By analyzing the patients cancer cells, then stratifying which chemotherapy drug or combination of drugs are most effective in treating that individual’s cancer, this live tissue protocol enhances the survival rate of the patient by ensuring that the initial round of chemo therapy is delivered correctly.   

The webinar will cover:

  • Why 25% accuracy of chemo treatments has become the accepted norm
  • Understanding value of live tissue MicK Assay Testing
  • Why measuring cancer cell apoptosis is critical
  • How chemo drug stratification improves the value of patient care and plan savings
  • Why a delivery system of this treatment through the healthplan is required

Oncology treatment and cost are typically at the top of the list of most expensive claims and often result in a member hitting their stop-loss max. Cost management activities around cancer have mostly been focused around dosage management, clinical path validation and specialty contract usage focused around centers of excellence. These have resulted in savings activities but are still not resolving the 75% of miss-directed first round chemotherapy treatments. By understanding the latest advancements in accurate identification of chemotherapy treatment assignment, plans will be able to establish best in practice protocols that result in 50% to 150% in additional saving in cancer care where chemotherapy is involved.   


 ABOUT THE PRESENTER: 
 Joe Hodges, President & CEO 
 INETICO, Inc.

 As an industry pioneer, Joseph identified the need to create electronic  medical cost solutions between care management products and the  medical claims experience. Through his risk mitigation vision, INETICO  brings Imagination, Innovation and Integration into the market place. His  overall goal is to establish simple solutions that drive employee health and  wellness initiatives.


Over the last 16 years, Joseph has worked in the medical cost containment field focused on clinical development programs in elder care, insurance product development and employer focused healthcare savings programs.


Currently he serves as the second vice chair on the Board of Directors at MOSI (the Museum of Science and Industry), as a member on the Moffitt Cancer Center Corporate Partners Steering Committee, and is a member of the Advisory Council for the Dali Museum.

Webinar Fees - 
$25/ea - HCAA Members
$100/ea - Non Members

 

5353 Wayzata Blvd. Suite 350
Minneapolis, MN 55416

Phone: 888.637.1605
Fax: 952.252.8096
Email: hcaainfo@hcaa.org

Copyright © Health Care Administrators Association (HCAA). All Rights Reserved.